3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
5
Meningioma
2
Glioblastoma
2
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroblastoma
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Medulloblastoma
1
Glioma
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Disease Progression
1
Carcinoid Tumor
1
Breast Neoplasms
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Nuclear Medicine Department, Hospital
6
Magnetic Resonance Spectroscopy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Biopsy
5
Temozolomide
4
Irinotecan
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dinutuximab
2
Cyclophosphamide
2
trametinib
1
tazemetostat
1
talazoparib
1
saponin QA-21V1
1
palbociclib
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
dabrafenib
1
Vincristine
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
lutetium Lu 177 dotatate
×
30 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled